Biomarkers in advanced larynx cancer
Carol R. Bradford(The Ohio State University), Thomas E. Carey(University of Michigan), Bhavna Kumar(Dehradun Institute of Technology University), Robbi A. Kupfer(University of Michigan), Avraham Eisbruch(University of Michigan–Ann Arbor), Mark E. Prince(University of Michigan), Jeremy M. G. Taylor(RAND Corporation), Jeffrey S. Moyer(Environmental Protection Agency), Celina G. Kleer(University of Michigan), Pawan Kumar(The Ohio State University), Norman D. Hogikyan(Michigan Medicine), Gregory T. Wolf(University of Michigan), Susan G. Urba(University of Michigan), Douglas B. Chepeha(University of Michigan), Jungwha Lee(Northwestern University), Emily Bellile(The Ohio State University), Kitrina G. Cordell(The Ohio State University), Nisha J. D’Silva(University of Michigan), Theodoros N. Teknos(University Hospitals Seidman Cancer Center), Francis P. Worden(Georgetown University)
Cited by 55
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Validation of an instrument to measure voice-related quality of life (V-RQOL)
|Journal of Voice|1999|1.1k
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974
|Proceedings of the National Academy of Sciences|2013|833
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766